RESPONDING TO PATIENT NEEDS!

Nitec Pharma AG is a specialty pharmaceutical company focused on the development and commercialization of innovative medicines and effective treatment solutions for chronic inflammation and pain-related diseases. The Company seeks to address areas of high unmet medical need within these markets by developing proprietary products based on well-characterized pharmaceuticals and disease targets.

Nitec’s most advanced product candidate is Lodotra, a circadian cytokine modulator, which successfully completed a European phase 3 trial in rheumatoid arthritis (RA) in 2006. A dossier was submitted in 2006 in order to obtain marketing authorization in 15 European countries using the decentralized procedure, and after successful completion of this decentralized procedure, the marketing authorization in these countries is expected in the second half of 2008. Nitec is conducting a second pivotal phase 3 trial in preparation for the filing of an NDA with the FDA seeking US approval of Lodotra for the treatment of the signs and symptoms of RA including morning stiffness. Lodotra is also being developed for the treatment of severe asthma and polymyalgia rheumatica (PMR).

Nitec’s second product candidate is TruNoc (tarenflurbil), which is being developed as a treatment of neuropathic pain, osteoarthritis and other chronic inflammation and pain-related diseases. Nitec is conducting pharmacokinetic studies in preparation for phase 2 trials in neuropathic pain and osteoarthritis.

Nitec is a spin-out of Merck KGaA and is headquartered in the Basel region of Switzerland.

Meet Nitec Pharma at the following conferences:

Sachs Associates 8th Annual Biotech in Europe Investor Forum
Swissôtel Zürich, Am Maktplatz Oerlikon,
Schulstrasse 44, CH-8050 Zürich
Wednesday 24th September 2008
Nitec Presentation Time: 10:45am

UBS Global Life Sciences Conference
Grand Hyatt Hotel in New York City
109 East 42nd Street, NY 10017
Thursday 25th September 2008
Nitec Presentation Time: 9:30am

Rodman & Renshaw 10th Annual Healthcare Conference, November 10-12, 2008 in New York

BIO-Europe 2008 14th Annual International Partnering Conference, November 17-19 in Mannheim/Heidelberg Germany
29/09/2008
Nitec Pharma AG secures funding of CHF 24M from TVM Capital and Deutsche Bank.
more
12/06/2008
Nitec to present Lodotra 12 month treatment data in Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR) in Paris.
more
22/01/2008
Nitec’s phase 3 results with Lodotra in RA published in current issue of The Lancet.
more
04/12/2007
Nitec Pharma appoints Hans Fünfschilling as Chairman…
more
space
space
space